Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours

被引：0
|
作者：
Lu, S. [1 ]
De Braud, F. G. M. [2 ]
Fan, Y. [3 ]
Hu, X. [4 ]
Ohe, Y. [5 ]
Yu, Y. [6 ]
Ahn, M-J. [7 ]
Cassier, P. [8 ]
Lin, J. J. [9 ]
Paz-Ares, L. [10 ]
Xue, C. [11 ]
Bordogna, W. [12 ]
Patel, S. [13 ]
Zeuner, H. [12 ]
Dong, X. [14 ]
机构：
[1] Shanghai Jiao Tong Univ, Dept Med Oncol, Shanghai Chest Hosp, Shanghai, Peoples R China
[2] Univ Milan, Med Oncol & Haematol Dept, Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] Zhejiang Canc Hosp, Dept Med Thorac Oncol, Hangzhou, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[5] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[6] Harbin Med Univ Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[7] Sungkyunkwan Univ, Sch Med, Dept Med, Seoul, South Korea
[8] Ctr Leon Berard, Dept Med, Lyon, France
[9] Massachusetts Gen Hosp, Ctr Thorac Canc, Boston, MA USA
[10] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[11] F Hoffmann La Roche Ltd, Biostat, Mississauga, ON, Canada
[12] F Hoffmann La Roche Ltd, Prod Dev Med Affairs, Basel, Switzerland
[13] Genentech Inc, Prod Dev Oncol, South San Francisco, CA USA
[14] Huazhong Univ Sci & Technol, Canc Ctr, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1852
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
666P
引用
收藏
页码：S468 / S469
页数：2
相关论文
共 50 条
  • [41] Larotrectinib in NTRK Fusion-Positive Locally Advanced or Metastatic Soft Tissue Sarcomas in Children: A Case Series
    Asarcikli, F.
    Kebudi, R.
    Sozmen, B. Oflaz
    Erbey, F.
    Buyukkapu, S. Bay
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S262 - S262
  • [42] ESMO 2018-Pooled Analysis confirms pan-Tumor Efficacy of Entrectinib in NTRK Fusion-positive Solid Tumors
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (12) : 796 - 796
  • [43] Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusion-positive, Recurrent or Advanced Solid Tumors
    Osman, Hind M.
    Tuncbilek, Meral
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (15) : 2602 - 2616
  • [44] Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
    Ahn, M.
    Cho, B. C.
    Siena, S.
    Drilon, A.
    De Braud, F.
    Krebs, M.
    John, T.
    Karapetis, C.
    Johnson, A.
    Chow-Maneval, E.
    Multani, P.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1783 - S1783
  • [45] Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib
    Dziadziuszko, Rafal
    Hung, Tiffany
    Wang, Kun
    Choeurng, Voleak
    Drilon, Alexander
    Doebele, Robert C.
    Barlesi, Fabrice
    Wu, Charlie
    Dennis, Lucas
    Skoletsky, Joel
    Woodhouse, Ryan
    Li, Meijuan
    Chang, Ching-Wei
    Simmons, Brian
    Riehl, Todd
    Wilson, Timothy R.
    MOLECULAR ONCOLOGY, 2022, 16 (10) : 2000 - 2014
  • [46] Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors
    Francois Mercier
    Nassim Djebli
    Mario González-Sales
    Felix Jaminion
    Georgina Meneses-Lorente
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 363 - 372
  • [47] Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors
    Bokemeyer, Carsten
    Vassal, Gilles
    Italiano, Antoine
    De la Cuesta, Esther
    Hiemeyer, Florian
    Fellous, Marc
    Marian, Marisca
    JCO PRECISION ONCOLOGY, 2021, 5 : 1458 - 1465
  • [48] Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (vol 31, S472, 2020)
    Liu, S. V.
    De Braud, F.
    Drilon, A.
    Doebele, R. C.
    Patel, M. R.
    Cho, B. C.
    Ahn, M. J.
    Chiu, C. H.
    Farago, A. F.
    Goto, K.
    Lee, J.
    Ohe, Y.
    Ou, S. H. I.
    Cassier, P.
    Tan, D. S. W.
    Otterson, G. A.
    Veronese, L.
    Osborne, S.
    Simmons, B.
    Siena, S.
    ANNALS OF ONCOLOGY, 2021, 32 (04) : 577 - 577
  • [49] EFFICACY AND SAFETY OF ENTRECTINIB IN CHILDREN WITHNTRK ORROS1 FUSION-POSITIVE (FP) PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
    Bagchi, Aditi
    Robinson, Giles W.
    Desai, Ami, V
    Wu, Yeming
    Wang, Huanmin
    Basu, Ellen M.
    Casanova, Michela
    van Tilburg, Cornelis M.
    Campbell-Hewson, Quentin
    Armstrong, Amy E.
    Andre, Nicolas
    Devlin, Clare
    Wulff, Jade
    Cardenas, Alison
    Hutchinson, Katherine E.
    Lian, Qinshu
    Ryklansky, Carolina
    Harmach, Vesna Sneller
    Fox, Elizabeth
    Gajjar, Amar
    NEURO-ONCOLOGY, 2024, 26
  • [50] Entrectinib in patients with advanced or metastatic NTRK fusion- positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
    Doebele, R. C.
    Drilon, A.
    Paz-Ares, L.
    LANCET ONCOLOGY, 2020, 21 (08): : E372 - E372
12345